Tag Archive for: antibody-drug conjugate

Phase 1 Trial for SHR-4394: PSMA-Targeted ADC Shows Early Activity in Advanced Prostate Cancer

/in , , /by

New results provide encouraging preliminary evidence of antitumor activity for SHR-4394, an investigational antibody-drug conjugate (ADC) targeting PSMA in metastatic castration-resistant prostate cancer (mCRPC). The findings come from a first-in-human 1hase 1 study evaluating SHR-4394 as a standalone treatment. The drug is designed to recognize PSMA, a protein frequently expressed on prostate cancer cells, and […]

Read more

UPDATE: ABBV-969 Shows Strong Molecular Responses in Advanced Prostate Cancer

/in , , /by

New biomarker data provide additional evidence of the preliminary activity of ABBV-969, an investigational antibody-drug conjugate (ADC) designed to target both PSMA and STEAP1 in metastatic castration-resistant prostate cancer (mCRPC). The findings come from the ongoing Phase 1 study, involving 49 heavily pretreated patients who had received a median of five previous treatment lines. Most […]

Read more

A STEAP1 ADC That May Turn Tumour Killing Into an Immune Response

/in , /by

A newly published study has introduced an interesting variation on antibody-drug conjugates (ADCs) for advanced prostate cancer: instead of simply delivering a toxic payload to cancer cells, the treatment is designed to help the immune system recognise what remains. The experimental ADC targets STEAP1, a cell-surface protein highly expressed in prostate cancer and already being […]

Read more

Phase 3 Trial Tests a New B7-H3 Strategy in Advanced Prostate Cancer

/in , , /by

A new phase 3 clinical trial is preparing to evaluate risvutatug rezetecan, or Ris-Rez or GSK5764227, in men with metastatic castration-resistant prostate cancer (mCRPC), an advanced form of prostate cancer that continues to progress despite androgen-deprivation treatment. The study, called EMBOLD Prostate-302, will compare this experimental therapy with best supportive or standard care, potentially including the […]

Read more

Soon to be Phase 1 Trial: AK157D1 a New B7‑H3–Targeted ADC in Advanced Prostate Cancer

/in , , /by

The investigational B7‑H3–targeting antibody–drug conjugate AK157D1, recently cleared for a Phase I trial in advanced solid tumors, is especially compelling from a prostate cancer perspective because B7‑H3 (CD276) is one of the most uniformly expressed and biologically aggressive surface targets across the full disease continuum, from hormone‑sensitive to castration‑resistant and neuroendocrine phenotypes. Unlike PSMA, which […]

Read more

UPDATE: ABBV-969 Shows Very Promising rFPS in mCRPC

/in , , /by

ABBV-969 is a dual-target antibody-drug conjugate targeting PSMA and STEAP1, data about its radiographic progression-free survival data have just been released, confirming a median rPFS of approximately 15 months in heavily pretreated metastatic castration-resistant prostate cancer. The study demonstrates a signal far exceeding the 4- to 5-month rPFS historically seen with cabazitaxel in the same […]

Read more

B7-H3 ADC YL201 Delivers Encouraging Results in Advanced mCRPC

/in , , /by

YL201 aka Tam-Peli (tambotatug pelitecan) , a B7-H3–targeting antibody–drug conjugate, is showing notable activity in advanced metastatic castration-resistant prostate cancer (mCRPC), including patients who have progressed after androgen receptor–targeted therapy and chemotherapy. In a phase 2 study of 82 heavily pretreated patients, the drug delivered a confirmed PSA50 response rate of 38.5%, an objective response […]

Read more

A New Immune‑Engaging ADC Platform: STEAP1‑Targeted Vandortuzumab–Exatecan

/in , , /by

Antibody–drug conjugates (ADCs) have transformed therapy in several malignancies, but in advanced prostate cancer they have mostly been evaluated for direct tumor cytotoxicity, with little attention to immune mechanisms that might underpin durable responses. A recent study introduces a new STEAP1‑targeted ADC platform built on vandortuzumab, an antibody directed at six‑transmembrane epithelial antigen of the […]

Read more

Phase 2 ARTEMIS-003 Trial: HS-20093 for mCRPC

/in , , /by

HS-20093  has received Breakthrough Therapy designation from China’s National Medical Products Administration for metastatic castration-resistant prostate cancer. The designation covers patients previously treated with novel endocrine therapy and taxane-based chemotherapy, a setting where later-line treatment options remain limited. HS-20093 is a B7-H3-targeted antibody-drug conjugate designed to bind tumor cells expressing B7-H3 and deliver a cytotoxic […]

Read more

Phase 1 Trial: Dual-Target ADC IDE034 Targets B7-H3/PTK7 in Prostate Cancer

/in , , /by

A promising new bispecific antibody-drug conjugate (ADC) known as IDE034 is entering early clinical testing in patients with advanced solid tumors, including prostate cancer, marking a potential step forward in precision oncology. This Phase 1a/1b trial, which began dosing its first patient in February 2026, targets tumors expressing both B7-H3 and PTK7, two surface proteins […]

Read more